Recently Published Articles, Papers and Newsletters

"Issue 3," TTC,llc Newsletter, 2009.

"Issue 2," TTC,llc Newsletter, 2009.

"Issue 1," TTC,llc Newsletter,2009.

"Issue 2," TTC,llc Newsletter, 2008.

 

• Two Worlds, One Planet. Glass H. Inside Outsourcing. pp 46-52. November 2009
• How to Manage Clinical Grant Costs, Glass H & Hollander K. Scrip Magazine. October 2009
• What Bothers Clinical Investigators, Glass H. Good Clinical Practice Journal. pp. 21-23, July 2009
• CRO Selection & Management, Glass H. & Beaudry D. Applied Clinical Trials, pp.48-54, April 2009
• The World’s Your Clinical Research Oyster. Glass H. Scrip Magazine. April 2009
• Investigator Attitudes toward Participation in Contract Research Organization-Managed Clinical Studies: A Survey of US Clinical Investigators. Glass H. Pharmaceutical Medicine. 23 (2): 85-90. 2009
• Investigator Dissatisfaction with the Conduct of Clinical Trials. Glass H. The Monitor. 23(4): 58-62, 2009
• Study Conduct a Big Part of the Budget. Glass H. Applied Clinical Trials. P. 14, January 2009
• Refutable Rates. Glass H. Applied Clinical Trials. P. 14, April 2009
• Reporting Concerns. Applied Clinical Trials. P. 14, July 2009
• CRO Selection & Management. Glass H. and Beaudry D. Applied Clinical Trials. pp. 48-54, April 2009
• Managing Clinical Grant Costs. Glass H. and Hollander K. Contemporary Clinical Trials. February 2009. doi:10.1016/j.cct.2009.02.001
• Pressure Points on Industry Executives: What Lies Ahead? Glass H & Poli L. International Journal of Pharmaceutical and Healthcare Marketing. Vol. 3, Iss. 1, 2009.
• The Profile of the One-Time 1572 Investigator. Glass H. Contemporary Clinical Trials. Vol. 30, pp. 34-39, 2009. doi:10.1016/j.cct.2008.09.008
• Global Clinical Trial Insight from TTC. Glass H. Applied Clinical Trials. P.16, September 2008
• The Importance of Medical Innovation in an Investigator's Decision to Take Part in Clinical Trials. Glass H. Drug Information Journal. Vol. 42, pp. 537-543, 2008.
• Key Factors in CRO Selection. Glass H., Beaudry D. Applied Clinical Trials. pp. 52-60, April 2008.
• Grant Budgeting and Negotiating in India and China. Jankosky J., Jiang Y., Farwell T. Applied Clinical Trials. pp. 56-62, November 2007.
• The CRO Crop. Glass H. and Beaudry D. Inside Outsourcing. pp. 56-63, November 2007.
• Outlook for Outsourcing. Glass H. Good Clinical Practice Journal. pp. 21-24, November 2007.
• The Demographic, Practice, and Prescribing Characteristics of US Clinical Investigators. Glass H and Beaudry D. Drug Information Journal. Vol. 41 pp. 645-651. 2007.
• Understanding Site Performance Differences in Multinational Phase III Clinical Trials. Glass H and DiFrancesco J. International Journal of Pharmaceutical Medicine. 21 (4): 279-286, 2007.
• Connecting the Dots. Glass H and Poli L. Pharmaceutical Executive. pp. 56-58, January 2007.
• Profiles of Phase IV Investigators and Subsequent Prescribing of the Study Drug. Glass H and Dalton D. Journal of Pharmaceutical Marketing and Management. 17 (3/4): 3-17, 2006.
• What is a Fair Market Value? Glass H. Good Clinical Practice Journal. pp. 23-25, August 2006.
• The 'L' Factor. Glass H. Scrip Magazine. November 2005.
• The Marketplace for Clinical Grants. Glass H. The Monitor. 19(4): 69-74, 2005.
• Follow the Phase III Leader. Glass H and Stefanacci R. Scrip Magazine. April 2005.
• Post-Launch Clinical Investigator Drug Prescribing in the US: The Behavior of Clinical Trial Investigators after Participating in Phase III Clinical Trials. Glass H and Rosenthal B. International Journal of Pharmaceutical Medicine. 16(2): 97-104, 2005.
• The Dual Role of Company Prescribing Loyalty in New Drug Launches. Glass H and Poli L. Journal of Pharmaceutical Marketing and Management. 16(2), 2004.
• Physician Participation in Clinical Studies and Subsequent Prescribing of New Drugs. Corrigan M and Glass H. Pharmacy and Therapeutics. 30(1): 60-66, 2005.
• Demographic, Practice and Prescribing Characteristics of Physicians Who Are Early Adopters of New Drugs. Glass H and Rosenthal R. Pharmacy and Therapeutics. 29(11): 699-708, 2004.
• Researchers as Marketers: Strengthen Relationships With Phase III Investigators for More Successful New Product Launches. Glass H. Pharmaceutical Executive. June 2004.
• Physician Participation in Market Support Clinical Studies and Subsequent Prescribing Behavior. Glass H. Journal of Pharmaceutical Marketing and Management. 15(4): 3-16, 2004.
• Do Clinical Grant Payment Practices in Phase 3 Clinical Trials Influence Subsequent Clinical Investigator Prescribing Behavior? Glass H. Disease Management. 7(1): 77-87, 2004.
• Patterns in Prescribing Behavior: The Potential Hidden Costs of Using CROs. Glass H. Drug Information Journal. 38: 105-112, 2004.
• Series of Regulatory Rulings Guide FDA Decision Making. Glass H. Drug Benefit Trends. Volume 15, October 2003; Supplement G. Presented in conjunction with: The 15th Annual Meeting of the Academy of Managed Care Pharmacy. April 10, 2003, Minneapolis, MN, USA.

contact reprints@ttc-llc.com for reprints of Published Papers